

REVIEW

Open Access



# Del Nido cardioplegia versus cold blood cardioplegia in adult cardiac surgery: a meta-analysis of randomized clinical trials

Congcong Li<sup>1</sup>, Haiyan Xiang<sup>1</sup>, Heng Yang<sup>1</sup>, Wu Liu<sup>1</sup>, Wanqi Lan<sup>1</sup>, Chao Luo<sup>1</sup>, Shuangjian Han<sup>1</sup>, Yongqin Li<sup>1</sup> and Yanhua Tang<sup>1\*</sup>

## Abstract

**Objective** Systematic evaluation of the safety of del Nido cardioplegia compared to cold blood cardioplegia in adult cardiac surgery.

**Methods** We systematically searched PubMed, EMBASE, The Cochrane Library and ClinicalTrials.gov for randomized clinical trials (published by 14 January 2024) comparing del Nido cardioplegia to cold blood cardioplegia in adult. Our main endpoints were myocardial injury markers and clinical outcomes. We assessed pooled data by use of a random-effects model or a fixed-effects model.

**Results** A total of 10 studies were identified, incorporating 889 patients who received del Nido cardioplegia and 907 patients who received cold blood cardioplegia. The meta-analysis results showed that compared with the cold blood cardioplegia, the del Nido cardioplegia had less volume of cardioplegia, higher rate of spontaneous rhythm recovery after cross clamp release, lower levels of postoperative cardiac troponin T and creatinine kinase-myocardial band, all of which were statistically significant. However, there was no statistically significant difference in postoperative troponin I and postoperative left ventricular ejection fraction. The clinical outcomes including mechanical ventilation time, intensive care unit stay time, hospital stay time, postoperative stroke, postoperative new-onset atrial fibrillation, postoperative heart failure requiring intra-aortic balloon pump mechanical circulation support, and in-hospital mortality of both are comparable.

**Conclusion** Existing evidence suggests that del Nido cardioplegia reduced volume of cardioplegia administration and attempts of defibrillation. The superior postoperative results in CTnT and CK-MB may provide a direction for further research on improvement of the composition of cardioplegia.

\*Correspondence:


Yanhua Tang  
tyh6565@163.com

<sup>1</sup>Department of Cardiovascular Surgery, The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University, Nanchang, Jiangxi Province 330006, China



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

## Visual Abstract



**Keywords** Cardioplegia, Myocardial protection, Randomized controlled trials, Meta-analysis

## Introduction

Mechanical arrest using cardioplegia remains the current gold standard for cardiac protection during cardiac surgery [1]. Cardioplegia can decrease myocardial energy consumption and ischemia reperfusion injury [2]. However, the selection of cardioplegia is entirely based on the experience and habits of the surgeons or perfusionist, and there is currently no unified guideline as a reference [3]. Myocardial protection has always been a daunting challenge for cardiac surgeons. Del Nido Cardioplegia (DNC) is an extracellular myocardial protection fluid that provides up to 90 min of myocardial protection after a single dose at 20 ml/kg [4]. In the early 1990s, Pedro del Nido and his team developed this solution to protect immature myocardial cells [5]. Delivery of del Nido solution was administered in a 1:4 ratio of blood to crystalloid [6]. In the past few decades, del Nido cardioplegia has been widely used for intraoperative myocardial protection of congenital heart disease [7]. Based on pediatric usage experience, del Nido was quickly applied to adult cardiac surgery for cardiac protection. Compared to traditional cold blood cardioplegia (blood to crystalloid ratio of 4:1), this solution has a higher dilution, the hallmark of del Nido cardioplegia is lidocaine supplement which acts as a sodium channel blocker that reduces intracellular sodium and calcium accumulation [8]. However, there are some physiological characteristic differences in tolerance of calcium damage and ischemia between infants and adults. It has not been universally acknowledged whether del Nido cardioplegia is safe for adults. This study systematically evaluates the safety of del Nido cardioplegia and cold blood cardioplegia in adult patients


undergoing cardiac surgery from the perspectives of myocardial protection and clinical outcomes, in order to provide new evidence for the application of del Nido cardiac arrest solution in adult cardiac surgery.

## Materials and methods

### Study design and inclusion/exclusion criteria

This systematic review and meta-analysis were performed in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) Statement and was registered in PROSPERO (ID: CRD42024502507). We applied the PICOS (Population, Intervention, Comparison, Outcome and Study design) criteria to define inclusion criteria:

1. Population: adult patients who underwent cardiac surgery requiring cardiopulmonary bypass (CPB) and myocardial arrest, regardless of race or nationality.
2. Intervention: Cardioplegia (DNC) was used for cardiac arrest.
3. Comparison: cold blood cardioplegia (CBC) was used for cardiac arrest.
4. Outcome: (1)Volume of cardioplegia (L); (2)CPB time (minute); (3)Aortic cross-clamp (ACC) time (minute); (4) Ventricular fibrillation after aortic cross-clamp removal; (5) Postoperative Cardiac Troponin I (CTnI) at 24 h after surgery (ng/ml); (6)Cardiac Troponin T (CTnT) at 24 h after surgery (ng/ml); (7) Postoperative Creatinine Kinase-Myocardial Band (CK-MB) at 24 h after surgery (U/L); (8)Postoperative left ventricular ejection



**Fig. 1** PRISMA flowchart of studies included in the meta-analysis

fraction (LVEF); (9)Mechanical ventilation time (hour); (10)Intensive care unit (ICU) stay time (day); (11)Hospital stay time (day); (12)Postoperative new-onset atrial fibrillation; (13)Postoperative stroke; (14) Postoperative intra-aortic balloon pump (IABP) requirement; (15)In-hospital mortality.

5. Study design: randomized clinical trial.

Exclusion criteria was defined as follows: (1)Non English literature; (2)Repeated publication literature; (3)Literature with incomplete original data.

### Search strategy

A comprehensive literature retrieval was performed by searching PubMed, EMBASE, the Cochrane Library, and ClinicalTrials.gov using search terms “del Nido” or “del-nido” and “cardioplegia” or “cardioplegic solution”. We selected randomized clinical trial (RCT) studies on the safety of del Nido cardioplegia compared to cold blood cardioplegia in adult cardiac surgery, the search deadline is from database establishment to 14 January 2024. The complete search used for PubMed was: (((del Nido) OR (del-nido)) AND (cardioplegia)) OR (cardioplegic

solution)) OR (cardioplegia solution). We considered all potentially eligible researches for review, regardless of the primary outcome or language. We also did a manual search, using the reference lists of key articles published in English.

### Data extraction and tabulation

Two double-blinded researchers (Congcong Li and Haiyan Xiang) independently screened literature, extracted data, tabulated intervention characteristics, and cross checked. If there are differences, they can be resolved through discussion or negotiation with third parties (Yanhua Tang). When selecting literature, first read the title, and after excluding obviously unrelated literature, further read the abstract and full text to determine whether to include it. If necessary, contact the original research author via email or phone to obtain uncertain but important information for this study. The content of data extraction includes: (1)Basic information of the included research: research title, first author, publication journal, publication year, etc.; (2)Baseline characteristics and intervention of the research subjects; (3)The key

**Table 1** Characteristics of included studies

Author & year	Country	Study period	Sample (N)	Gender (Male, N)		Mean age (year)		Operation procedure	Hypertension (N) DNC/CBC	Diabetes (N) DNC/CBC	Clinical outcome
				DNC	CBC	DNC	CBC				
Garcia-Suarez 2022 [16]	Spain	2018.06-2019.09	474	143	148	65.60±11.94	65.30±11.93	Mix	147/151	17/21	(2)(3)(4)(6)(8)(9)(10)(11)(12)(13)(14)(15)
Zhang 2022 [17]	China	2021.01-2021.09	133	37	36	54.50±7.21	56.20±6.71	Mix	19/18	NA	(1)(2)(3)(4)(5)(7)(8)(9)(10)(12)
Demir 2022 [15]	Turkey	2019.07-2021.02	213	79	88	60.56±10.24	61.07±9.36	CABG	61/66	47/38	(12)(13)(14)(15)
Moktan Lama 2021 [13]	Nepal	2018.05-2019.09	90	36	38	59.98±8.96	57.51±9.71	CABG	16/19	15/20	(1)(2)(3)(5)(7)(8)(9)(10)(11)(15)
Urcun 2021 [14]	Turkey	2017.01-2020.01	300	114	126	57.64±12.66	61.78±11.33	CABG	72/60	45/27	(2)(3)(6)(7)(8)(9)(10)(11)(12)(14)(15)
Gunnaydin 2020 [12]	USA	2017.01-2019.06	220	61	72	71.00±8.00	73.00±10.00	CABG	83/92	72/80	(1)(3)(8)(9)(10)(11)(12)(14)(15)
Kirisci 2020 [11]	Turkey	2019.07-2020.01	60	20	22	59.03±11.58	62.00±11.53	CABG	14/13	12/14	(1)(2)(3)(4)(10)(11)(12)(15)
Sanetra 2019 [4]	Poland	2016.06-2018.06	150	48	38	62.53±12.69	63.83±10.99	AVR	50/51	13/16	(1)(2)(3)(4)(6)(7)(8)(11)(12)(13)(15)
Kanathut 2019 [10]	Thailand	2017.02-2017.11	89	24	32	64.85±9.96	65.94±9.96	Mix	36/36	17/15	(1)(2)(3)(4)(6)(7)(8)(10)(12)(13)(14)(15)
Ad 2018 [9]	USA	2015.02-2016.04	89	40	31	65.30±7.90	65.10±9.10	CABG/VS	35/32	22/15	(1)(2)(3)(4)(5)(13)

DNC: del Nido cardioplegia, CBC: cold blood cardioplegia, Mix: mix operation, CABG: coronary artery bypass grafting, AVR: atrial valve replacement, VS: valve surgery, (1)Volume of cardioplegia; (2)Cardiopulmonary bypass time; (3)Aortic cross-clamp time; (4) Ventricular fibrillation after aortic cross-clamp removal; (5) 24 h postoperative Troponin I levels; (6) Troponin T levels at 24 h after surgery; (7)24 h postoperative Creatinine Kinase-Myocardial Band levels; (8)Postoperative left ventricular ejection fraction; (9)Mechanical ventilation time; (10) Intensive care unit stay time; (11)Hospital stay time; (12)Postoperative new-onset atrial fibrillation; (13)Postoperative stroke; (14) postoperative heart failure requiring intra-aortic balloon pump mechanical circulation support; (15)In-hospital mortality

elements of bias risk assessment; (4)Outcome indicators and outcome measurement data of concern.


**Quality of evidence assessment**

Two independent researchers assessed the risk for bias included in the study and cross checked the results. The bias risk assessment for included RCT studies was conducted using the bias risk assessment tool recommended in Cochrane Handbook 5.1.0.


**Statistical analysis**

Meta-analysis was performed using RevMan5.3 software. Measurement data were reported as mean±standard deviation (SD) or median (interquartile range), Comparative data between cohorts are shown as mean differences (MD), and relative risk (RR) was used as effect analysis statistic for dichotomous variables, with 95% confidence interval (CI) provided for each effect size. Heterogeneity among the included studies was analyzed using the  $\chi^2$  (Q) test (with a test level of  $\alpha=0.1$ ), and the heterogeneity was evaluated by combining  $I^2$ . When the P value of


A




B



C



D



**Fig. 2** Meta-analyses of del Nido cardioplegia versus cold blood Cardioplegia, comparing the cardioplegia volume, CPB time, ACC time and intraoperative defibrillation. **A**, Cardioplegia volume; **B**, CPB time; **C**, ACC time; **D**, Defibrillation

Q test was less than 0.1 or I<sup>2</sup> was greater than 50%, significant heterogeneity was shown among the studies, and the random effect model was used for Meta-analysis; otherwise, the fixed effect model was used. If there was statistical heterogeneity among the studies, the source of heterogeneity was further analyzed, and the random effect model was used for analysis after excluding the influence of obvious clinical heterogeneity. P < 0.05 was considered statistically significant. Obvious clinical

heterogeneity was processed by subgroup analysis or sensitivity analysis, or descriptive analysis only.


## Results

### Study selection and baseline characteristics


A total of 4896 relevant literature were obtained in the initial examination, and after layer by layer screening, 10 RCT studies [4, 9–17] were finally included, with a total of 1796 adult patients, including 889 patients in the DNC group and 907 patients in the CBC group. The literature




A




B



C



D



**Fig. 3** Meta-analyses of del Nido cardioplegia versus cold blood Cardioplegia, comparing the levels of myocardial injury markers 24 h after surgery and postoperative left ventricular ejection fraction. **A**, CTn I; **B**, CTn T; **C**, CK-MB; **D**, LVEF


screening process and results are shown in Fig. 1. The basic characteristics of the included studies are shown in Table 1.

The 10 RCT studies were all published between 2018 and 2023 (Table 1). Mean trial duration was 18 months (range 9 months to 36 months). More than half of patients underwent Coronary artery bypass grafting (CABG) surgery and three included studies focusing on mixed adult cardiac surgery procedures, one trail focused on aortic valve replacement (AVR) surgery, and one trail included adult patients who underwent CABG or valve surgery (VS) surgery. All 10 randomized trials were single-center; one study was stopped early [9], one study was s finished with a delay due to the coronavirus pandemic situation [15]. 3 were registered in Clinicaltrials.gov [4, 9, 16], and 1 was registered in Thai clinical trial registry [10], 5 trials reported detailed descriptions of methods

for generating random sequence [9, 12, 14–16], 3 trials specified blind method for participants [4, 12, 16]. The results of bias risk assessment of included studies are shown in Supplementary Figures S1.

**Intraoperative outcome**

Seven studies assessed intraoperative reperfusion volume of cardioplegia. Pooling data of these studies showed that DNC led to lower volume during operation than CBC [MD=-1.06, 95%CI (-1.49, -0.63), P<0.0001] (Fig. 2). Six studies assessed ventricular fibrillation after aortic cross-clamp removal. The results of meta-analysis showed that the defibrillation requirement was lower in the DNC group (Fig. 2). and the DNC group had a higher spontaneous cardiac rhythm recovery rate [MD=0.37, 95%CI (0.30, 0.45), P<0.00001]. Eight and nine studies respectively assessed CPB time and ACC time. Pooling the data



**Fig. 4** Meta-analyses of del Nido cardioplegia versus cold blood Cardioplegia, comparing clinical outcome. Outcomes assessed are **(A)** Mechanical ventilation time, **(B)** Intensive care unit stay time, **(C)** Hospital stay time, **(D)** Postoperative new-onset atrial fibrillation, **(E)** Postoperative stroke, **(F)** postoperative heart failure requiring intra-aortic balloon pump mechanical circulation support, and **(G)** In-hospital mortality. For each estimate, the grey shaded area is the weight of the estimate in proportion to the overall effect

of these studies showed no significant difference in the CPB time [MD=-1.95, 95%CI (-5.08, 1.18),  $P=0.22$ ] and ACC time [MD=-6.19, 95%CI (-13.12, 0.74),  $P=0.08$ ] with DNC compared with CBC (Fig. 2).

#### Levels of myocardial injury biomarker and postoperative cardiac function

Three, four and five studies assessed the levels of CTnI, CTnT and CK-MB at 24 h after surgery, respectively. The results showed that compared with the CBC group, the CTnI level in the DNC group had no significant difference [MD= -0.26, 95%CI (-0.96, 0.44),  $P=0.47$ ]. The CTnT level and CK-MB level in the DNC group were significantly lower than those in the CBC group [MD=-0.47, 95%CI (-0.91, -0.04),  $P=0.03$ ; MD=-2.29, 95%CI (-3.97, -0.61),  $P=0.008$ ] (Fig. 3).

Seven studies assessed postoperative LVEF, there were no differences in preoperative ejection fraction in selected studies. Pooling the data of these studies showed that the postoperative LVEF in DNC group was better than that in CBC group, and the difference between the two groups was not statistically significant [MD=0.73, 95%CI (-0.44, 1.89),  $P=0.22$ ] (Fig. 3).

#### Postoperative clinical outcome

Five, seven and six studies were included in the evaluation of mechanical ventilation time, ICU stay time and hospital stay, respectively. The results of meta-analysis showed that there were no statistically significant differences in mechanical ventilation time, ICU stay time and hospital stay between DNC group and CBC group [MD=-0.17, 95%CI (-0.46, -0.13),  $P=0.27$ ; MD=-0.02, 95%CI (-0.34, -0.30),  $P=0.92$ ; MD=0.12, 95%CI (-0.04, 0.28),  $P=0.14$ ] (Fig. 4).

The incidence of postoperative adverse events such as new atrial fibrillation, stroke, IABP support, and hospital death were evaluated. The results of meta-analysis showed that there were no statistically significant differences between the DNC group and the CBC group in postoperative adverse events, including postoperative new-onset atrial fibrillation, stroke, IABP requirement and in-hospital mortality [MD=0.86, 95%CI (0.60, 1.22),  $P=0.4$ ; MD=0.56, 95%CI (0.30, 1.08),  $P=0.09$ ; MD=0.97, 95%CI (0.59, 1.59),  $P=0.90$ ; MD=1.25, 95%CI (0.62, 2.51),  $P=0.54$ ] (Fig. 4).

#### Sensitivity analysis and publication bias assessment

Sensitivity analysis showed that there was no significant change in the combined effect size of outcome indicators after one article was excluded separately. The funnel-plot was used to evaluate publication bias, the points in the image converge into a roughly symmetrical (inverted) funnel (Supplementary Figures S2).

## Discussion

It is necessary to quickly arrest the heart before cardiac surgery. In order to better restore the function of myocardium after ischemia, the concept of cardioplegia is proposed [18]. With the development of cardiac surgery, the research on myocardial protection has been going on for decades, and the establishment of the overall theoretical system of myocardial protection and the clinical practice methods are becoming more and more mature. The three important components of cardiac arrest fluid to protect myocardium include: (1) Increase the extracellular  $K^+$  and  $Mg^{2+}$  concentrations, and reduce the inflow of  $Na^+$  and  $Ca^{2+}$  to reduce their intracellular concentrations; (2) low temperature to reduce the needs of cell metabolism; (3) Nutrients [8]. The commonly used cardioplegia solution in clinical practice includes cold blood cardioplegia (CBC) prepared with high potassium solution and blood at 1:4, intracellular histidine-tryptophane-ketoglutarate solution, extracellular liquid St. Thomas solution, etc. Del Nido cardioplegia was used in adults as an extracellular cardioplegia has been a new trend, which is formulated with high potassium crystal fluid and blood in a 4:1 formula. It has lower viscosity than traditional cold blood cardioplegia and can provide better perfusion of the myocardium [19]. It was originally designed for the immature myocardium of children, because only a single perfusion can provide myocardial protection for 90 min, ensure the continuity of surgery, and have a clear protective effect on the immature myocardium of children. In recent years, this cardioplegia solution has also been applied in adult cardiac surgery. Several studies have shown that del Nido cardioplegia solution also has high safety and effectiveness in adult cardiac surgery. Del Nido cardioplegia applied in adults is a new method of myocardial protection, while the clinical application of del Nido cardioplegia for mature myocardium protection is still insufficient.

This study was a meta-analysis of RCT studies of del Nido cardioplegia and cold blood cardioplegia in adult cardiac surgery. The result showed that del Nido cardioplegia was correlated with cardioplegia perfusion volume, intraoperative defibrillation requirement, levels of postoperative CTnT and CK-MB and postoperative LVEF. It did not increase CPB time, ACC time, postoperative CTnI, postoperative new-onset atrial fibrillation, postoperative stroke, postoperative IABP use rate, nor did it increase postoperative mechanical ventilation time, length of ICU stays, length of hospital stays, and mortality. Magnetic resonance imaging (MRI) likely represents the most thorough method to assess myocardial protection with special attention to the subendocardial myocardium and its viability. The recommendation that postoperative MRI scan be done from postoperative days 5 to 7 or another standardized time range to assess



myocardial protection was proposed in future randomized trials of del Nido cardioplegia versus conventional cardioplegia [20].

Del Nido cardioplegia is a kind of single dose cardioplegia. The first infusion dose is generally 20 ml/kg and up to a maximum of 1 L, which can satisfy the cross-clamp time of 90 min. If the cardiac arrest time needs to be extended, the intraoperative infusion amount is generally added at the dose of 10 ml/kg. The results of several studies have shown that the perfusion volume of del Nido cardioplegia is significantly lower than that of blood-containing cardioplegia requiring repeated perfusion [21, 22]. In this review, 7 RCT studies involving intraoperative cardioplegia volume were systematically evaluated, and the results were consistent with published studies showing that the use of del Nido cardioplegia in adult cardiac surgery significantly reduced the use of cardioplegia. Less cardioplegia can reduce blood dilution in patients and reduces postoperative transfusion. The research objects in the ten RCT studies only included patients who underwent CABG surgery or valvular surgery. For complex operations with long operation time, such as operations on large vessels, there is no consensus on how del Nido cardioplegia should be used for additional perfusion after adult heart surgery exceeding 90 min and the interval of additional perfusion, which requires further study. A retrospective study found that the use of del Nido cardioplegia in adult cardiac surgery reduced the need for defibrillation after cardioversion following intraoperative circulatory arrest [23]. The results of this study support this conclusion. The success rate of spontaneous rhythm recovery after intraoperative circulation arrest in the del Nido cardioplegia group is higher than that in the cold blood cardioplegia group, and the need for defibrillation is lower.

Troponin is released from damaged cell membranes only after cardiac muscle cells have died, and both CTnT and CTnI are ideal for detecting myocardial damage [24]. CK-MB is an important biomarker in the diagnosis of myocardial injury, and it is used as a potential auxiliary detection index in combination with troponin to reflect the degree of myocardial injury [25]. Del Nido cardioplegia was associated with lower CTnT and CK-MB after cardiac surgery in a meta-study [26] that included only 2 RCT studies. A recent meta-analysis [27] about del Nido cardioplegia in myocardial protection included 3 RCT studies and showed no statistically significant difference in CTnT and CTnI levels 24 h after cardiac surgery between the DNC group and the CBC group. Among the 10 RCT studies included in this study, there were 3, 4 and 5 studies involving the levels of CTnI, CTnT and CK-MB at 24 h after surgery with complete data, respectively. The results showed that DNC significantly reduced the levels of CTnT and CK-MB compared with CBC. There

was no significant difference in postoperative CTnI. Partial researches [21, 28] showed that del Nido cardioplegia were significantly better than the blood cardioplegia group in improving postoperative LVEF. Another retrospective study showed that del Nido cardioplegia were comparable to cold blood cardioplegia in patients with reduced ejection fraction ( $EF < 40\%$ ), with no difference in postoperative EF levels. This study systematically evaluates the postoperative LVEF levels of del Nido cardioplegia and cold blood cardioplegia, and the results supported that the postoperative ejection fraction of del Nido cardioplegia was comparable with cold blood cardioplegia. Further RCT researches are needed to investigate the protective effect of DNC on myocardium.

The base solution of Del Nido cardioplegia is a non-glucose solution, which can reduce perioperative blood glucose elevation and postoperative insulin use to a certain extent [29]. The optimization of blood glucose management indicates an improvement in clinical efficacy. In the 10 studies included, only 2 RCT study assessed intraoperative blood glucose levels. One study compared the intraoperative blood glucose levels at the 5th minute after removal of the aortic cross-clamp, the glucose values favor the del Nido cardioplegia, but statistical significance was not reached. Another study compared intraoperative baseline blood glucose and peak blood glucose levels respectively. Intravenous peak blood glucose levels and insulin requirements were significantly lower in the del Nido cardioplegia group.

Although del Nido cardioplegia has shown beneficial effects on myocardial protection in adult cardiac surgery, there was no significant difference between DNC and CBC in terms of clinical outcomes, including duration of mechanical ventilation, length of stays in ICU, length of hospital stays, and postoperative adverse events.

Limitations of this study: Inotrope requirements and intraoperative echocardiography were not assessed due to incomplete data [2]. Although all RCT studies were included in this study, some RCT assignment hiding and blinding methods were unclear, which may lead to bias in selection, implementation and measurement; [3] Among the studies included in this review, the volume of cardioplegia single dose, the interval and dose of additional infusion, and the mode of infusion could not be unified. Although sensitivity analysis was performed, heterogeneity still could not be eliminated; [4] The sample size of the included studies is small and the number of studies is small, so it is necessary to increase the sample size to obtain exact evidence.

## Conclusion

Existing evidence suggests that del Nido cardioplegia reduced volume of cardioplegia administration and attempts of defibrillation. The superior postoperative

results in CTnT and CK-MB may provide a direction for further research on improvement of the composition of cardioplegia. Limited by the number and quality of included studies, the conclusions of this study need to be verified by multi-center randomized controlled studies with higher quality and large samples.

#### Abbreviations

ACC	Aortic cross-clamp
AVR	Aortic valve replacement
CABG	Coronary artery bypass grafting
CBC	Cold blood cardioplegia
CI	Confidence interval
CK	MB-Creatinine Kinase-Myocardial Band
CPB	Cardiopulmonary bypass
CTn	Cardiac Troponin
DNC	Del Nido Cardioplegia
LVEF	Left ventricular ejection fraction
IABP	Intra-aortic balloon pump
ICU	Intensive care unit
MRI	Magnetic resonance imaging
RCT	Randomized clinical trial
RR	Relative risk
SD	Standard deviation
VS	Valve surgery

#### Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s13019-024-02846-0>.

Supplementary Material 1

#### Author contributions

Congcong Li: Data curation; Formal analysis; Methodology; Writing—original draft. Haiyan Xiang: Data curation; Methodology; Writing—review & editing. Heng Yang: Writing—review & editing; Wu Liu: Writing—review & editing; Wanqi Lan: Conceptualization; Data curation; Formal analysis; Writing—original draft; Writing—review & editing. Chao Luo: Data curation; Writing—review & editing; Shuangjian Han: Formal analysis; Writing—original draft; Yongqin Li: Writing—original draft; Yanhua Tang: Conceptualization; Supervision; Writing—review & editing. All authors reviewed the manuscript.

#### Funding

Funded by the National Natural Science Foundation of China (82360105 & 81960058), the Natural Science Foundation of Jiangxi Province (20232ACB206001), the Key Research and Development Program of Jiangxi Province (20223BBG71010 & 20212BBG71012) and the Clinical trial research projects (2021efyA02).

#### Data availability

All relevant data are within the manuscript and its Supporting Information files.

#### Declarations

##### Ethics approval and consent to participate

Not applicable.

##### Consent for publication

Not applicable.

##### Competing interests

The authors declare no competing interests.

Received: 24 February 2024 / Accepted: 14 June 2024

Published online: 22 June 2024

#### References

1. Chambers DJ, Fallouh HB. Cardioplegia and cardiac surgery: pharmacological arrest and cardioprotection during global ischemia and reperfusion. *Pharmacol Ther.* 2010;127(1):41–52.
2. Buckberg GD, Athanasuleas CL. Cardioplegia: solutions or strategies? *Eur J Cardiothorac Surg.* 2016;50(5):787–91.
3. Ferguson ZG, Yarborough DE, Jarvis BL, Sistino JJ. Evidence-based medicine and myocardial protection—where is the evidence? *Perfusion.* 2015;30(5):415–22.
4. Sanetra K, Gerber W, Shrestha R, Domaradzki W, Krzych Ł, Zembala M, Cisowski M. The Del Nido versus cold blood cardioplegia in aortic valve replacement: a randomized trial. *J Thorac Cardiovasc Surg.* 2020;159(6):2275–e831.
5. Matte GS, del Nido PJ. History and use of Del Nido cardioplegia solution at Boston Children's hospital. *J Extra Corpor Technol.* 2012;44(3):98–103.
6. Buel ST, Striker CW, O'Brien JE. Del nido versus St. Thomas Cardioplegia Solutions: a single-center retrospective analysis of Post Cross-clamp Defibrillation Rates. *J Extra Corpor Technol.* 2016;48(2):67–70.
7. Isildak FU, Yavuz Y. Comparison of Del Nido and Blood Cardioplegia in Pediatric patients undergoing Surgical repair for congenital heart disease. *Pediatr Cardiol.* 2021;42(6):1388–93.
8. Whittaker A, Aboughdir M, Mahbub S, Ahmed A, Harky A. Myocardial protection in cardiac surgery: how limited are the options? A comprehensive literature review. *Perfusion.* 2021;36(4):338–51.
9. Ad N, Holmes SD, Massimiano PS, Rongione AJ, Fornaresio LM, Fitzgerald D. The use of Del Nido Cardioplegia in adult cardiac surgery: a prospective randomized trial. *J Thorac Cardiovasc Surg.* 2018;155(3):1011–8.
10. Kantathut N, Cherntanomwong P, Khajareen S, Leelayana P. Lactated Ringer's as a base solution for Del Nido Cardioplegia. *J Extra Corpor Technol.* 2019;51(3):153–9.
11. Kirisci M, Kocarlan A, Altintas Aykan D, Alkan Baylan F, Doganer A, Orak Y. Evaluation of the cardioprotective effects of crystalloid Del Nido cardioplegia solution via a rapid and accurate cardiac marker: heart-type fatty acid-binding protein. *Turk J Med Sci.* 2020;50(4):999–1006.
12. Gunaydin S, Gunertem OE, Babaroglu S, Kunt AT, McCusker K, Ozisik K. Clinical outcomes of single-dose cardioplegia in high-risk coronary bypass. *Asian Cardiovasc Thorac Ann.* 2021;29(2):77–83.
13. Moktan Lama PB, Khakural P, Sigdel S, Raj Bhatta M, Sah Teli R, Baral RK, et al. Del Nido Cardioplegia in Coronary artery bypass grafting surgery: a safe, efficacious and economic alternative to St. Thomas solution; an experience from a developing nation. *Perfusion.* 2021;36(5):470–5.
14. Urcun YS, Pala AA. Comparison of Microplegia Solution and Del Nido Cardioplegia Solution in Coronary artery bypass grafting surgery: which one is more effective? *Heart Surg Forum.* 2021;24(5):E842–8.
15. Demir D, Balci AB, Kahraman N, Sunbul SA, Gucu A, Seker IB, et al. The comparison of Del nido cardioplegia and crystalloid-based blood cardioplegia in adult isolated coronary bypass surgery: a randomized controlled trial. *Niger J Clin Pract.* 2022;25(12):1998–2004.
16. Garcia-Suarez J, Garcia-Fernandez J, Martinez Lopez D, Reques L, Sanz S, Carballo D, et al. Clinical impact of Del Nido Cardioplegia in adult cardiac surgery: a prospective randomized trial. *J Thorac Cardiovasc Surg.* 2023;166(5):1458–67.
17. Zhang X, Du Y, Wang A. Protective efficacy on adult ischemic myocardium under bypass: Del Nido vs. St. Thomas Blood Cardioplegia. *Ann Thorac Cardiovasc Surg.* 2023;29(3):125–32.
18. Melrose DG, Dreyer B, Bentall HH, Baker JB. Elective cardiac arrest. *Lancet.* 1955;269(6879):21–2.
19. Negi SL, Mandal B, Singh RS, Puri GD. Myocardial protection and clinical outcomes in tetralogy of Fallot patients undergoing intracardiac repair: a randomized study of two cardioplegic techniques. *Perfusion.* 2019;34(6):495–502.
20. Waterford SD, Ad N. Del Nido Cardioplegia: questions and (some) answers. *J Thorac Cardiovasc Surg.* 2023;165(3):1104–8.
21. Kuserli Y, Turkyilmaz S, Turkyilmaz G, Kavala AA. Comparison of Del Nido Cardioplegia and Blood Cardioplegia in Aortic Root surgery. *Heart Surg Forum.* 2020;23(3):E376–84.

22. Eris C, Engin M, Erdolu B, Kagan As A. Comparison of Del Nido Cardioplegia vs. blood cardioplegia in adult aortic surgery: is the single-dose cardioplegia technique really advantageous? *Asian J Surg.* 2022;45(5):1122–7.
23. Elassal AA, Al-Ebrahim K, Al-Radi O, Zaher ZF, Dohain AM, Abdelmohsen GA, et al. Myocardial protection by blood-based Del Nido versus St. Thomas Cardioplegia in Cardiac surgery for adults and children. *Heart Surg Forum.* 2020;23(5):E689–95.
24. Agewall S, Giannitsis E. Troponin elevation in coronary ischemia and necrosis. *Curr Atheroscler Rep.* 2014;16(3):396.
25. Xu C, Zhang T, Zhu B, Cao Z. Diagnostic role of postmortem CK-MB in cardiac death: a systematic review and meta-analysis. *Forensic Sci Med Pathol.* 2020;16(2):287–94.
26. Zhai K, Cheng X, Zhang P, Wei S, Huang J, Wu X, et al. Del Nido Cardioplegia for myocardial protection in adult cardiac surgery: a systematic review and update meta-analysis. *Perfusion.* 2023;38(1):6–17.
27. Malvindi PG, Tian DH, Bifulco O, Berretta P, Alfonsi J, Cefarelli M, et al. Del nido versus blood cardioplegia in adult cardiac surgery: a meta-analysis. *J Cardiovasc Med (Hagerstown).* 2023;24(8):522–9.
28. Sanetra K, Gerber W, Domaradzki W, Mazur M, Synak M, Pietrzyk E, et al. Del Nido versus cold blood cardioplegia in adult patients with impaired ejection fraction undergoing valvular and complex heart surgery. *J Cardiovasc Surg (Torino).* 2023;64(1):112–20.
29. Mick SL, Robich MP, Houghtaling PL, Gillinov AM, Soltesz EG, Johnston DR, et al. Del nido versus Buckberg Cardioplegia in adult isolated valve surgery. *J Thorac Cardiovasc Surg.* 2015;149(2):626–34. discussion 34–6.

### Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.